Analyzing Aurinia Pharmaceuticals (AUPH) and Its Rivals

Aurinia Pharmaceuticals (NASDAQ: AUPH) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Aurinia Pharmaceuticals to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, dividends and valuation.

Valuation and Earnings

This table compares Aurinia Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aurinia Pharmaceuticals $170,000.00 -$23.29 million -4.16
Aurinia Pharmaceuticals Competitors $290.27 million $35.99 million 59.99

Aurinia Pharmaceuticals’ peers have higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and target prices for Aurinia Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals 0 0 6 0 3.00
Aurinia Pharmaceuticals Competitors 1148 3465 11979 242 2.67

Aurinia Pharmaceuticals presently has a consensus target price of $12.00, indicating a potential upside of 118.58%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.19%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than its peers.

Institutional & Insider Ownership

28.1% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 49.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Aurinia Pharmaceuticals has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals’ peers have a beta of 1.41, meaning that their average share price is 41% more volatile than the S&P 500.

Profitability

This table compares Aurinia Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals -18,089.02% -25.56% -20.72%
Aurinia Pharmaceuticals Competitors -5,400.85% -161.62% -35.75%

Summary

Aurinia Pharmaceuticals peers beat Aurinia Pharmaceuticals on 7 of the 13 factors compared.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply